Autoantigen characterization in liver/kidney microsome positive hepatitis

Digestive and Liver Disease

Volumn 32, Issue 1, 2000, Pages 39-45

  Clemente, M G ^a   De Virgiliis, S ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Osp Regionale per le Microcitemie   (Italy)

Author keywords

Autoantibody; Chronic hepatitis; Cytochrome P450 enzyme; Liver kidney microsome

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CYTOCHROME P450;

ANTIBODY DETECTION; ANTIGEN RECOGNITION; AUTOIMMUNE HEPATITIS; CHRONIC HEPATITIS; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOFLUORESCENCE; KIDNEY MICROSOME; LIVER MICROSOME; MULTIPLE ENDOCRINE ADENOMATOSIS; REVIEW; TOXIC HEPATITIS; VIRUS HEPATITIS; WESTERN BLOTTING;

EID: 0034029781     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1590-8658(00)80043-2     Document Type: Review

References (34)

1. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973;15:331-44.
2. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;7:1333-9.
3. Homberg JC, Andre C, Abuaf N. A new anti-liver kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 1984;55:561-70.
4. Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol 1992;33:183-6.
5. Crivelli O, Lavarini C, Rizzetto M. Microsomal autoantibodies in chronic infections with HBsAg associated delta agent. Clin Exp Immunol 1983;54:232-8.
6. Lenzi M, Ballardini G, Fusconi M, Cassani F, Selleri L, Volta U, et al. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet 1990;335:258-9.
7. Clemente MG, Meloni A, Obermayer-Straub P, Frau F, Manns MP, De Virgiliis S. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998;114:324-8.
8. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II. Proc Natl Acad Sci USA 1988;85:8256-60.
9. Philipp T, Durazzo M, Trautwein C, Alex B, Straub P, Lamb JG, et al. Recognition of uridine-diphosphate glucuronosyl transferase by LKM-3 antibodies in chronic hepatitis-D. Lancet 1994;344:578-81.
10. Clemente MG, Obermayer-Straub P, Meloni A, Strassburg CP, Arangino V, Tukey RH, et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab 1997;82:1353-61.
11. Lecoeur S, Andre C, Beaune PH. Tienilic acid-induced autoimmune hepatitis: anti-liver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol Pharmacol 1996;50:326-33.
12. Robin MA, Maratrat M, Le Roy M, Le Breton FP, Bonierbale E, Dansette P, et al. Antigenic targets in tienilic acid hepatitis - Both cytochrome P450 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J Clin Invest 1996;98:1471-80.
13. Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M. et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-4501A2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest 1990;85:1967-73.
14. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 1998;39:S8-16.
15. Israel Y. Antibodies against ethanol-derived protein adducts: pathogenic implications. Gastroenterology 1997;113:353-5.
16. Bourdi M, Chen W, Peter RM, Martin JL, Buters JT, Nelson SD, et al. Human cytochrome P450 2E1 is a major autoantigens associated with halothane hepatitis. Chem Res Toxicol 1996;9:1159-66.
17. Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced and autoimmune liver disease. Hepatology 1997;26:1054-66.
18. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman D, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996;6:1-42.
19. Guengerich FP. Human cytochrome P450 enzymes. In: Oritz de Montellano PR, editor. Cytochrome P450 structure, mechanism and biochemistry. New York-London: Plenum Press; 1995. p. 473-537.
20. Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, et al. Human anti-endoplasmic reticulum autoantibodies appearing in drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA 1987;84:551-5.
21. Volta U, De Franceschi L, Lari F, Molinaro N, Zoli M, Bianchi FB. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998;352:26-9.
22. Pritchard MP, Ossetian R, Li DN, Henderson CJ, Burchell B, Wolf CR, et al. A general strategy for the expression of recombinant human cytochrome P450s in Escherichia coli using bacterial signal peptides: expression of CYP3A4, CYP2A6 and CYP2E1. Arch Biochem Biophys 1997;345:342-54.
23. Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg JC. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988;8:1662-6.
24. Durazzo M, Philipp T, Van Pelt FN, Luttig B, Borghesio E, Michel G, et al. Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology 1995;108:455-62.
25. Muratori L, Lenzi M, Ma Y, Cataleta M, Mieli-Vergani G, Vergani D, et al. Heterogeneity of liver/kidney microsomal antibody type 1 in autoimmune hepatitis and hepatitis C virus related liver disease. Gut 1995;37:406-12.
26. Yamamoto AM, Cresteil D, Homberg JC, Alvarez F. Characterization of anti liver-kidney microsome antibody (anti-LKM-1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993;104:1762-7.
27. Miyakawa H, Matsushima H, Narita Y, Hankins RW, Kitazawa E, Fujikawa H, et al. Differences in antigenic sites, recognized by anti-liver-kidney microsome-1 (LKM-1) autoantibody, between HCV-positive and HCV-negative sera in Japanese patients. J Gastroenterol 1998;33:529-35.
28. Dalekos GN, Wedemeyer H, Obermayer-Straub P, Kayser A, Barut A, Frank H, et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 1999;30:366-75.
29. nd Annual Meeting of ESPGHAN, June 2-5, 1999, Warsaw, Poland.
30. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
31. Perheentupa J. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Horm Metab Res 1996;28:353-6.
32. Rosatelli MC, Meloni A, Meloni A, Devoto M, Cao A, Scott HS, et al. A common mutation in Sardinian autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy patients. Hum Genet 1998;103:428-34.
33. Manns MP, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987;1:292-4.
34. Stechemesser E, Klein R, Berg PA. Characterization and clinical relevance of liver-pancreas antibodies in autoimmune hepatitis. Hepatology 1993;18:1-9.